Literature DB >> 24423593

Simultaneous LC-MS/MS quantification of P-glycoprotein and cytochrome P450 probe substrates and their metabolites in DBS and plasma.

Marija Bosilkovska1, Julien Déglon, Caroline Samer, Bernhard Walder, Jules Desmeules, Christian Staub, Youssef Daali.   

Abstract

BACKGROUND: An LC-MS/MS method has been developed for the simultaneous quantification of P-glycoprotein (P-gp) and cytochrome P450 (CYP) probe substrates and their Phase I metabolites in DBS and plasma. P-gp (fexofenadine) and CYP-specific substrates (caffeine for CYP1A2, bupropion for CYP2B6, flurbiprofen for CYP2C9, omeprazole for CYP2C19, dextromethorphan for CYP2D6 and midazolam for CYP3A4) and their metabolites were extracted from DBS (10 µl) using methanol. Analytes were separated on a reversed-phase LC column followed by SRM detection within a 6 min run time.
RESULTS: The method was fully validated over the expected clinical concentration range for all substances tested, in both DBS and plasma. The method has been successfully applied to a PK study where healthy male volunteers received a low dose cocktail of the here described P-gp and CYP probes. Good correlation was observed between capillary DBS and venous plasma drug concentrations.
CONCLUSION: Due to its low-invasiveness, simple sample collection and minimal sample preparation, DBS represents a suitable method to simultaneously monitor in vivo activities of P-gp and CYP.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24423593     DOI: 10.4155/bio.13.289

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  14 in total

Review 1.  Alternative Sampling Strategies for Cytochrome P450 Phenotyping.

Authors:  Pieter M M De Kesel; Willy E Lambert; Christophe P Stove
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

2.  Why dried blood spots are an ideal tool for CYP1A2 phenotyping.

Authors:  Pieter M M De Kesel; Willy E Lambert; Christophe P Stove
Journal:  Clin Pharmacokinet       Date:  2014-08       Impact factor: 6.447

3.  Case Report: Opioid Use Disorder Associated With Low/Moderate Dose of Loperamide in an Intellectual Disability Patient With CYP3A and P-Glycoprotein Reduced Activity.

Authors:  Vincent Guinchat; Nicolas Ansermot; Kuntheavy Ing Lorenzini; Dimitri Politis; Youssef Daali; Chin B Eap; Séverine Crettol
Journal:  Front Psychiatry       Date:  2022-06-23       Impact factor: 5.435

4.  Evaluation of phenoconversion phenomenon in obese patients: the effects of bariatric surgery on the CYP450 activity "a protocol for a case-control pharmacokinetic study".

Authors:  Hengameh Ghasim; Mohammadreza Rouini; Kheirollah Gholami; Farnoosh Larti; Saeed Safari; Yalda H Ardakani
Journal:  J Diabetes Metab Disord       Date:  2021-07-31

5.  Chronic administration of caderofloxacin, a new fluoroquinolone, increases hepatic CYP2E1 expression and activity in rats.

Authors:  Li Liu; Ming-xing Miao; Ze-yu Zhong; Ping Xu; Yang Chen; Xiao-dong Liu
Journal:  Acta Pharmacol Sin       Date:  2016-02-01       Impact factor: 6.150

6.  Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots.

Authors:  M Bosilkovska; C F Samer; J Déglon; M Rebsamen; C Staub; P Dayer; B Walder; J A Desmeules; Y Daali
Journal:  Clin Pharmacol Ther       Date:  2014-04-10       Impact factor: 6.875

7.  Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study).

Authors:  Célia Lloret-Linares; Youssef Daali; Sylvie Chevret; Isabelle Nieto; Fanny Molière; Philippe Courtet; Florence Galtier; Raphaëlle-Marie Richieri; Sophie Morange; Pierre-Michel Llorca; Wissam El-Hage; Thomas Desmidt; Frédéric Haesebaert; Philippe Vignaud; Jerôme Holtzmann; Jean-Luc Cracowski; Marion Leboyer; Antoine Yrondi; Fabienne Calvas; Liova Yon; Philippe Le Corvoisier; Olivier Doumy; Kyle Heron; Damien Montange; Siamak Davani; Julien Déglon; Marie Besson; Jules Desmeules; Emmanuel Haffen; Frank Bellivier
Journal:  BMC Pharmacol Toxicol       Date:  2017-11-07       Impact factor: 2.483

8.  Simultaneous Determination of Five Cytochrome P450 Probe Substrates and Their Metabolites and Organic Anion Transporting Polypeptide Probe Substrate in Human Plasma Using Liquid Chromatography-Tandem Mass Spectrometry.

Authors:  Jae-Kyung Heo; Hyun-Ji Kim; Ga-Hyun Lee; Boram Ohk; Sangkyu Lee; Kyung-Sik Song; Im Sook Song; Kwang-Hyeon Liu; Young-Ran Yoon
Journal:  Pharmaceutics       Date:  2018-07-02       Impact factor: 6.321

9.  Interaction between Fexofenadine and CYP Phenotyping Probe Drugs in Geneva Cocktail.

Authors:  Marija Bosilkovska; Gaelle Magliocco; Jules Desmeules; Caroline Samer; Youssef Daali
Journal:  J Pers Med       Date:  2019-10-02

10.  Evaluation of Phenotypic and Genotypic Variations of Drug Metabolising Enzymes and Transporters in Chronic Pain Patients Facing Adverse Drug Reactions or Non-Response to Analgesics: A Retrospective Study.

Authors:  Victoria Rollason; Célia Lloret-Linares; Kuntheavy Ing Lorenzini; Youssef Daali; Marianne Gex-Fabry; Valérie Piguet; Marie Besson; Caroline Samer; Jules Desmeules
Journal:  J Pers Med       Date:  2020-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.